Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Gabrielle Sulzberger, a director at Eli Lilly & Co, acquired 11 shares of common stock through a deferral plan.

Summary

• Gabrielle Sulzberger, a director of Eli Lilly & Co, acquired 11 shares of common stock on October 21, 2024.
• The shares were acquired at a price of $906.13 per share.
• These shares were acquired through the Lilly Directors' Deferral Plan, in lieu of cash compensation.
• The shares will be settled in common stock following Ms. Sulzberger's separation from service.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed positively as it aligns director interests with shareholders. There is no indication of any negative sentiment.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the director's separation from service.

Industry Context

Director share acquisitions are a common occurrence and are often seen as a positive sign of confidence in the company's future prospects.

Comparison to Industry Standards

• Director share acquisitions are a common practice across publicly traded companies.
• The use of deferral plans for director compensation is also a standard practice.
• The specific details of the deferral plan and the timing of settlement are specific to Eli Lilly's compensation policies.

Stakeholder Impact

• The share acquisition by a director may be viewed positively by shareholders as it indicates confidence in the company.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, Stock Units, Form 4, Gabrielle Sulzberger